glp-1 cardiovascular outcome trials Forest plot showing outcomes across major RA Review of Cardiovascular Outcome Trials

In 2023, branded obesity drug sales reached $6 billion, and this figure is expected to grow exponentially as demand continues to rise and these medications are used to treat a broader range of diseases

NF-B, nuclear factor kappa-light-chain enhancer of activated B cells

Some pharmacies also use unusual concentrations like 2.4 mg/mL or 3.33 mg/mL

Begin your GLP-1 and Hormonal Health Chicago journey today with a free virtual consultation with a doctor to see if Wegovy or Zepbound is right for you

REFERENCES Badkar AV et al, Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements